ALS drug Relyvrio withdrawn from market after failed clinical trial

(CNN)– A relatively new drug to treat ALS is being pulled from the shelves.

Today, Amylyx Pharmaceuticals announced it is voluntarily withdrawing Relyvrio from the market.

The FDA approved the drug in September 2022. The decision was controversial.

At the time, some said there wasn’t enough proof it was helpful.

A more recent and larger trial showed no evidence that Relyvrio worked.

The company says patients who are currently on it should talk to their doctor.